Skip to main content

Temporal and Pharmacokinetic Aspects in Delivery of Peptides and Proteins

  • Chapter
Book cover Delivery Systems for Peptide Drugs

Part of the book series: NATO ASI Series ((NSSA,volume 125))

  • 137 Accesses

Abstract

The rational administration of any drug to a patient requires some knowledge of the anticipated efficacy and toxicity for a particular dose of that drug. When an understanding of how an individual patient will absorb and eliminate a drug is coupled together with knowledge of the pharmacologic effects of a given amount of the drug, a particular dose can be selected that will result in clinical efficacy and minimal toxicity. Such considerations have been defined adequately for many classical drugs; however, this approach has not been used as yet for the new peptide and protein therapeutic agents. Thus, today we are interested in gaining an understanding of the pharmacokinetics and pharmacodynamics of peptide and protein drugs. Pharmacokinetics may be simply described as the mathematical relationship that exists between the dose of a drug and the measureable concentration in a readily accessible site in the body (e.g., plasma or blood). Pharmacodynamics extends this relationship to a correlation between measured concentrations of drug and the pharmacologic effect. As a simple description, pharmacokinetics describes what the body does to the drug, as opposed to pharmacodynamics which describes what the drug does to the body. There are two major uses for pharmacokinetics. First, as a tool in therapeutics to help the clinician choose the right dosage regimen for a particular drug in a specific patient. Second, pharmacokinetics may be used as a tool in defining drug disposition. As indicated above, up to the present time the therapeutic use of pharmacokinetics for proteins and peptide drug compounds has not been realized. However, regulatory agencies do require information concerning drug disposition which can be best described using pharmacokinetic principles, i.e., the use of pharmacokinetics as a tool in defining drug disposition.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 169.00
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 219.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 219.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  • Benet, L.Z., 1984, Pharmacokinetic parameters; which are necessary to define a drug substance? Eur. J. Resp. Dis., 65(Suppl 134):45–61.

    Google Scholar 

  • Binder, C., Lauritzen, T., Faber, O. and Pramming, S., 1984, Insulin pharmacokinetics, Diabetes Care, 7: 188–199.

    Article  PubMed  Google Scholar 

  • Bocci, V., 1985, Distribution, catabolism and pharmacokinetics of interferons, in: “Interferon, Vol.4,” Finter, N.B. and Oldham, R., eds., Elsevier, Amsterdam.

    Google Scholar 

  • Foon, K.A. Sherwin, S.A., Abrams, P.G., Stevenson, H.C., Holmes, P., Maluish, A.E., Oldham, R.K. and Herberman, R.B., 1985, A phase I trial of recombinant gamma interferon in patients with cancer, Cancer Immunol. Immunother., 20: 193–197.

    Article  PubMed  CAS  Google Scholar 

  • Hotchkiss, A., Ross, M., Refino, C., Chen, S., Fuller, G. and Baughman, R.A., 1987, Circulation, submitted for publication.

    Google Scholar 

  • Korninger, C., Stassen, J.M., and Collen, D., 1981, Turnover of human extrinsic (tissue-type) plasminogen activator, Thromb. Haemostas. (Stuttgart), 46: 658–661.

    CAS  Google Scholar 

  • Kurzrock, R., Rosenblum, M.G., Sherwin, S.A., Rios, A. Talpaz, M. Quesada, J.R., and Gutterman, J.U., 1985, Pharmacokinetics, single-dose tolerance, and biological activity of recombinant α-interferon in cancer patinets, Cancer Res., 45: 2866–2872.

    PubMed  CAS  Google Scholar 

  • Nestor, J.J., Ho, T.L., Tahilrami, R., McRae, G.I., and Vickery, B.H., 1984, Long acting LH-RH agonists and antagonists, Int. Cong. Ser.-Excerpta Med., 656: 24–35.

    CAS  Google Scholar 

  • Owens, D.R., Hayes, T.M., Alberti, K.G.M.M., Jones, M.K., Heding, L.G., Home, P.D., and Burrin, J.M., 1981, Comparative study of subcutaneous, intramuscular, and intravenous administration of human insulin, Lancet, 1: 118–122.

    Article  Google Scholar 

  • Rijken, D.C., Hoylaerts, M., and Collen, D., 1982, Fibrinolytic properties of one-chain and two-chain human extrinsic (tissue-type) plasminogen activator, J. Biol. Chem., 257:2920–2925.

    PubMed  CAS  Google Scholar 

  • Vadhan-Raj, S., Al-Katib, A., Bhalla, R., Pelus, L., Nathan, C.F., Sherwin, S.A., Oettgen, H.F., and Krown, S.E., 1986, Phase I trial of recombinant interferon gamma in cancer patients, J. Clin. Oncol., 4: 137–146.

    PubMed  CAS  Google Scholar 

  • Van der Burg, M., Edelstein, M., Gerlis, L., Liang, C-M., Hirschi, M., and Dawson, A., 1985, Recombinant interferon-γ (Immuneron): Results of a phase I trial in patients with cancer, J. Biol Response Modifiers, 4: 264–272.

    Google Scholar 

  • Waldhäusl, W.K. Bratush-Marrain, P.R. Vierhapper, H., and Nowotny, P., 1983, Insulin pharmacokinetics following continuous infusion and bolus injection of regular porcine and human insulin in healthy man. Metabolism, 32: 478–486.

    Article  PubMed  Google Scholar 

  • Wills, R.J., Dennis, S., Spiegel, H.E., Gibson, D.M., and Nadler, P.I., 1984, Interferon kinetics and adverse reactions after intravenous, intramuscular, and subcutaneous injection, Clin. Pharmacol. Ther., 35: 722.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Editor information

Editors and Affiliations

Rights and permissions

Reprints and permissions

Copyright information

© 1986 Springer Science+Business Media New York

About this chapter

Cite this chapter

Benet, L.Z., Baughman, R.A. (1986). Temporal and Pharmacokinetic Aspects in Delivery of Peptides and Proteins. In: Davis, S.S., Illum, L., Tomlinson, E. (eds) Delivery Systems for Peptide Drugs. NATO ASI Series, vol 125. Springer, Boston, MA. https://doi.org/10.1007/978-1-4757-9960-6_6

Download citation

  • DOI: https://doi.org/10.1007/978-1-4757-9960-6_6

  • Publisher Name: Springer, Boston, MA

  • Print ISBN: 978-1-4757-9962-0

  • Online ISBN: 978-1-4757-9960-6

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics